ARTICLE | Clinical News
LymphoRad-131: HGSI submitted an IND to begin a Phase I trial.
January 28, 2002 8:00 AM UTC
Human Genome Sciences Inc. (HGSI), Rockville, Md. Product: LymphoRad-131 Business: Cancer Therapeutic category: Immune stimulation Target: B lymphocytes Description: 131-radiolabeled BLyS (B lymphocy...